SYR-472 Open-label Study

Phase 3

Completed

• Conditions: Diabetes Mellitus
• Interventions: Drug: SYR-472

• Registration Number: NCT01751360
• Lead Sponsor: Takeda

Brief Summary

To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-12-13
• Study First Submitted QC: 2012-12-13
• Study First Posted: 2012-12-18
• Study Start: 2013-04-01
• Primary Completion: 2013-08-01
• Study Completion: 2013-08-01
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-07
• Last Update Posted: 2023-12-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

-1. The participant is judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.

2. The participant can sign and date a written, informed consent form prior to the initiation of any study procedures.

Exclusion Criteria

-1. The participant has concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease

. 2. The participant is assessed to be ineligible for the study by the investigator or subinvestigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
SYR-472 100mg	SYR-472	SYR-472 100mg

Primary Outcome Measures

Name	Time	Method
Blood Glucose	7 days	Blood Glucose